Wang Y has described the preliminary safety and antitumor efficacy of pyrotinib (a pan-HER receptor tyrosine kinase inhibitor) by studying tumoroids and corresponding xenografts derived from tumor samples from patients with HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma [174]. This evidence concerns the gene ERBB2 and lung adenocarcinoma.